EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Rituximab With or Without Chemotherapy for Anti‐ MAG Neuropathy: A Retrospective Multicenter Real‐World Study

Emilien Delmont iD, Pascal Cintas iD, Céline Tard, José Boucraut, Laurent Magy iD, Simon Frachet iD, Céline Labeyrie iD, Andoni Echaniz-Laguna iD, Nicolas Noel iD, Juliette Svahn iD, Antoine Pegat iD, Françoise Bouhour und 19 weitere

Journal of the Peripheral Nervous System · 2026-12 · 31 (4)

DOI: 10.1111/jns.70175 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 30.09.2026. Verfasst von Emilien Delmont und 30 weiteren Autor:innen. Beteiligte Einrichtung: Referral Center for Neuromuscular Diseases and ALS, La Timone Hospital, Aix-Marseille University, Marseille, France. Hauptthemen laut MEDLINE: Immunologic Factors, Myelin-Associated Glycoprotein, Peripheral Nervous System Diseases, Rituximab. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims In anti‐myelin‐associated glycoprotein (MAG) neuropathy, the efficacy of rituximab (RTX) is not demonstrated in randomized controlled trials. Combinations of RTX with conventional chemotherapy (immunochemotherapy, ICT) may provide potential benefit, but systematic evaluations are lacking. We aimed to compare the efficacy and safety of RTX and ICT in a multicenter retrospective real‐world cohort.

Methods

Patients with anti‐MAG antibody titers > 10 000 Buhlmann titer units (BTUs) were included. Treatment response was defined as an improvement of ≥ 1 point in the Overall Neuropathy Limitation Scale (ONLS) compared to baseline. Propensity score matching was used to account for differences in baseline characteristics between treatment groups.

Results

A total of 230 patients were included: 150 received RTX and 80 received ICT. Mean follow‐up was 4 years (range, 1–20 years). One year after treatment, clinical improvement occurred in 61/147 (41%) patients treated with RTX and 39/78 (50%) treated with ICT (OR = 1.4 [0.8–2.5] p = 0.3). At last follow‐up, clinical improvement occurred in 55/150 (37%) patients treated with RTX and 31/80 (39%) treated with ICT (OR = 1.1 [0.6–1.9] p = 0.8). Propensity score matching yielded similar results. Among ICT regimens, dexamethasone–RTX–cyclophosphamide was associated with the highest response rate. RTX induction, 1 g days 1 and 15, seemed superior to four‐weekly infusions. Adverse events were more frequent with ICT than with RTX (28% vs. 15%; OR = 2.20 [1.07–4.54], p = 0.02).

Interpretation

In this cohort, adding chemotherapy to RTX was not associated with greater long‐term improvement, despite a higher rate of adverse events. Prospective controlled studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunologic FactorsMyelin-Associated GlycoproteinPeripheral Nervous System DiseasesRituximabAgedFemaleHumansMaleMiddle AgedCyclophosphamideDrug Therapy, CombinationRetrospective Studies

Stichwörter der Autor:innen

anti‐MAG neuropathyimmunochemoterapyrituximab

Substanzen

CyclophosphamideImmunologic FactorsMAG protein, humanMyelin-Associated GlycoproteinRituximab

Autor:innen und Institutionen

  • Referral Center for Neuromuscular Diseases and ALS, La Timone Hospital, Aix-Marseille University, Marseille, France.
  • Referral Center for Neuromuscular Diseases, AOC, CHU Toulouse Purpan, Toulouse, France.
  • Referral Center for Neuromuscular Diseases, Inserm 1172, Lille University Hospital, Lille, France.
  • Immunology Department, La Timone Hospital, Marseille, France.
  • Reference Center for Rare Peripheral Neuropathies, UR 20218, University Hospital of Limoges, Limoges, France.
  • Referral Centre for Rare Neuropathies (CERAMIC), Le Kremlin-Bicêtre, France.

ORCID-Profile: Emilien Delmont, Pascal Cintas, Laurent Magy, Simon Frachet, Céline Labeyrie, Andoni Echaniz-Laguna, Nicolas Noel, Juliette Svahn, Antoine Pegat, Florent Cluse, Angela Puma, Armelle Magot, Thierry Gendre, Violaine Planté-Bordeneuve, Jean-Baptiste Chanson, Tania Stojkovic, Jean-Baptiste Noury, Jean-Philippe Camdessanché, Louis Poncet-Mongemont, Aude-Marie Grapperon, Etienne Fortanier, Shahram Attarian

Zitieren

APA

Delmont, E., Cintas, P., Tard, C., Boucraut, J., Magy, L., Frachet, S., Labeyrie, C., Echaniz-Laguna, A., Noel, N., Svahn, J., Pegat, A., Bouhour, F., Cluse, F., Puma, A., Magot, A., Farnault, L., Aurran Schleinitz, T., Gendre, T., Planté-Bordeneuve, V., …, & Attarian, S. (2026). Rituximab With or Without Chemotherapy for Anti‐ MAG Neuropathy: A Retrospective Multicenter Real‐World Study. Journal of the Peripheral Nervous System, 31(4). https://doi.org/10.1111/jns.70175

Vancouver

Delmont E, Cintas P, Tard C, Boucraut J, Magy L, Frachet S, et al. Rituximab With or Without Chemotherapy for Anti‐ MAG Neuropathy: A Retrospective Multicenter Real‐World Study. Journal of the Peripheral Nervous System. 2026;31(4). doi:10.1111/jns.70175

BibTeX
@article{Delmont2026,
  author = {Delmont, Emilien and Cintas, Pascal and Tard, Céline and Boucraut, José and Magy, Laurent and Frachet, Simon and Labeyrie, Céline and Echaniz-Laguna, Andoni and Noel, Nicolas and Svahn, Juliette and Pegat, Antoine and Bouhour, Françoise and Cluse, Florent and Puma, Angela and Magot, Armelle and Farnault, Laurent and Aurran Schleinitz, Thérèse and Gendre, Thierry and Planté-Bordeneuve, Violaine and Dormeuil, Alice and Cassereau, Julien and Chanson, Jean-Baptiste and Mallaret, Martial and Stojkovic, Tania and Noury, Jean-Baptiste and Taieb, Guillaume and Camdessanché, Jean-Philippe and Poncet-Mongemont, Louis and Grapperon, Aude-Marie and Fortanier, Etienne and Attarian, Shahram},
  title = {Rituximab With or Without Chemotherapy for Anti‐ MAG Neuropathy: A Retrospective Multicenter Real‐World Study},
  journal = {Journal of the Peripheral Nervous System},
  year = {2026},
  volume = {31},
  number = {4},
  doi = {10.1111/jns.70175}
}
Kostenlos starten →